- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00218621
The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1
February 20, 2013 updated by: Lauren M. Jansson, Johns Hopkins University
Maternal Buprenorphine Administration and Fetal/Infant Neurobehavior
The purpose of this study is to evaluate the effects of drugs used by treatment providers on the fetuses and infants of opiate dependent women.
The subjects in this study are women enrolled in a large, multi-site, double blind study that looks at the effects of methadone and buprenorphine treatment during pregnancy.
This study will evaluate fetal and maternal biophysiologic data longitudinally during pregnancy to determine how these substances may affect fetal neurobehavior.
Additionally, infant neurobehavioral assessments and measurements of infant vagal tone will be collected to see how methadone and buprenorphine differentially affect the neonatal abstinence syndrome, or "withdrawal" in exposed neonates.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Previous research by this group has found that methadone treatment during pregnancy directly impacts fetal neurophysiology independently of maternal physiology.
Buprenorphine is a new therapy for opiate dependent individuals, and its use during pregnancy is currently being evaluated.
Some research has shown that buprenorphine lessens the neonatal abstinence syndrome when compared to methadone.
Thirty methadone and 30 buprenorphine maintained women will be evaluated at 24, 28, 32 and 36 weeks gestation using a state-of-the-art computerized fetal actocardiograph and data analysis program to simultaneously evaluate fetal movement and heart rate and maternal physiologic parameters.
Investigators will be blinded to treatment group.
Longitudinal neurodevelopment of the fetuses in each group will be explored.
The differential effects of methadone and buprenorphine on the neonatal abstinence syndrome will also be explored.
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224 6823
- The Center for Addiction and Pregnancy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Opioid dependent pregnant women enrolled in parent study (Maternal Opioid treatment: Human Experimental Research)
Description
Inclusion Criteria:
- generally healthy opiate dependent women
- currently enrolled in the study "Maternal Opioid Treatment, Human Experimental Research study
- uncomplicated singleton pregnancies
Exclusion Criteria:
- complications of pregnancy, including HIV, diabetes, polyhydramnios, hypertension, preterm labor or placenta previa
- evidence of fetal malformation
- significant maternal health problems, including HIV infection
- significant maternal psychopathology that would preclude informed consent, including schizophrenia
- alcohol dependency per DSM IV criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fetal heart rate
Time Frame: up to 300 minutes
|
up to 300 minutes
|
Fetal movement
Time Frame: up to 300 minutes
|
up to 300 minutes
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Neonatal abstinence syndrome
Time Frame: 4 days
|
4 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Lauren M. Jansson, M.D., Johns Hopkins University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2005
Primary Completion (Actual)
February 1, 2009
Study Completion (Actual)
February 1, 2009
Study Registration Dates
First Submitted
September 20, 2005
First Submitted That Met QC Criteria
September 20, 2005
First Posted (Estimate)
September 22, 2005
Study Record Updates
Last Update Posted (Estimate)
February 21, 2013
Last Update Submitted That Met QC Criteria
February 20, 2013
Last Verified
February 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Narcotic-Related Disorders
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Respiratory System Agents
- Antitussive Agents
- Buprenorphine
- Methadone
Other Study ID Numbers
- 04032202
- DPMCDA (Other Identifier: NIDA)
- R01DA019934 (U.S. NIH Grant/Contract)
- NIDA R01DA019934
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Turku University HospitalUniversity of TurkuCompleted
-
Hopital Antoine BeclereUnknown
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
Clinical Trials on Buprenorphine / methadone
-
Karolinska University HospitalSchering-Plough; Region Stockholm; Swedish National Drug Policy CoordinatorCompleted
-
University Hospital, Clermont-FerrandCSAPA ANPAA 63UnknownOpiate Dependent | Previous Illicit Drug UseFrance
-
Johns Hopkins UniversityCompleted
-
Oregon Health and Science UniversityHanoi Medical University; Hennepin Healthcare Research InstituteCompletedHIV | Substance Related DisordersVietnam
-
Merck Sharp & Dohme LLCCompleted
-
Elizabeth Krans, MDNational Institute on Drug Abuse (NIDA); OpalGenix, IncRecruitingPregnancy Related | Opioid Use DisorderUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Montefiore Medical Center; Fordham UniversityCompletedHIV Infections | HIV | Opioid-Related DisordersUnited States
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA)Completed
-
National Development and Research Institutes, Inc.National Institute on Drug Abuse (NIDA); New York City Department of Health... and other collaboratorsCompleted
-
University Hospital, CaenCompletedNeonatal Abstinence SyndromeFrance